Assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) and other tumor types.
MPLN offers SP263 immunohistochemical testing for the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded tissue.PD-L1 expression level utilizing this clone has been associated with response to durvalumab (IMFINZI, AstraZeneca UK Limited).
Immunohistochemistry, Technical component (TC) available
This assay utilizes the VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody (VENTANA PD-L1 (SP263)) which is a rabbit monoclonal primary antibody directed against the programmed deathligand1 (PD-L1) B7 homolog 1 (B7-H1, CD274). The antibody detects the extracellular domain of PD-L1 and produces membranous and/or cytoplasmic staining.
Paraffin embedded tissue block
3 slides (3-5 uM) per marker on adhesion glass
Ship ambient. Protect from extreme temperature with an ice pack. Separate ice pack from specimen.
Improper specimen labeling; Insufficient sample; Inadequate fixation and/or processing
Quantitative in Tumor Infiltrating Lymphocytes (TILs): Cut off POSITIVE in =/>25% of tumor infiltrating lymphocytes (TILs); NEGATIVE (no reactivity in tumor infiltrating lymphocytes, <25%)
PD-L1 IHC is indicated as an aid in the assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) and other tumor types. PD-L1 is a critical immune regulatory molecule which can be expressed by tumor cells as a mechanism to escape immune surveillance. Assessment of tumor PD-L1 protein levels may have prognostic and/or therapeutic significance in some cancer patients. Identifying PD-L1 expression on tumor cells may help determine which patients will most benefit from anti-PD-1/PD-L1 therapy.